<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
   "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
<meta http-equiv="Content-Language" content="ja" />
<meta name="google-site-verification" content="78bXa4jGt2PrqLzfpcc3iROE9kVG_lWcQ1gDJNiWCNA" />
<meta name="Keywords" content="NPOJIP,KUSURINOCHECK,Pharmacovigilancefor Evidence-Based Healthcare" />
<meta name="Description" content="NPOJIP Med Check TIP" />
<meta http-equiv="Content-Style-Type" content="text/css" />
<meta http-equiv="Content-Script-Type" content="text/javascript" />
<link rel="icon" type="image/png" href="../../images/logoicon.png" title="NPOJIP" />
<link rel="stylesheet" type="text/css" href="../../css/tip2.css" media="all" />
<title>Med Check in English</title>
<!-- 更新日 2019/09/10  00:37:00 -->
</head>
<body>
<div class="wrapper">
	<div id="contents">
		<img src="../../images/english/medchecktip.jpg" width="760" />
		<a href="../../index.html"><img src="../../images/english/home.jpg" width="80" /></a>

	<div style="text-align:center">
		<span style="font-weight:bold">
		<span style="font-size:xx-large">M</span><span style="font-size:x-large">ED </span><span style="font-size:xx-large">C</span><span style="font-size:x-large">HECK </span><br />
			bimonthly<br />
		<span style="font-style:italic">launched on Jan 2015 in Japan, integrating two ISDB member bulletins:</span>
			<br />Med Check<br />
		</span>

<p>Rigorously Independent and reliable Information for informed
decision-making on treatment and healthcare, published by
Non-Profit Organization Japan Institute of Pharmacovigilance
(NOPJIP).  Med Check is financed by its subscribers.
No advertising, No shareholders, No sponsors.</p>

<p><span style="color:#bc0101"><span style="font-weight:bold"><span style="font-size:x-large">Here is the 14th issue of “Med Check” in English</span></span></span><br />
We will publish at least three issues a year</p>

		</div>
<table border="2" bordercolor="#ffcccc" cellpadding="2" cellspacing="0" align="center" width="80%">
	<tr>
		<th>Apr. 2019,Vol.5, No.14</th><th><a href="medchecktip.html#Vol5-No14">Contents</a></th><th><a href="Med&#32;Check&#32;Tip-14-2019-9-10.pdf">PDF(6.9MB)</a></th>
	</tr>
	<tr>
		<th>Apr. 2019,Vol.5, No.13</th><th><a href="medchecktip.html#Vol5-No13">Contents</a></th><th><a href="Med&#32;Check&#32;Tip-13-2019-5-3.pdf">PDF(6.1MB)</a></th>
	</tr>
	<tr>
		<th>Dec. 2018,Vol.4, No.12</th><th><a href="medchecktip.html#Vol4-No12">Contents</a></th><th><a href="Med&#32;Check-TIP&#32;12-12-18.pdf">PDF(8.5MB)</a></th>
	</tr>
	<tr>
		<th>Aug. 2018,Vol.4, No.11</th><th><a href="medchecktip.html#Vol4-No11">Contents</a></th><th><a href="Med&#32;Check-TIP&#32;11-08-29.pdf">PDF(4.2MB)</a></th>
	</tr>
	<tr>
		<th>Apr. 2018,Vol.4, No.10</th><th><a href="medchecktip.html#Vol4-No10">Contents</a></th><th><a href="Med&#32;Check-TIP&#32;10-05-09.pdf">PDF(2.9MB)</a></th>
	</tr>
	<tr>
		<th>Dec. 2017,Vol.3, No.9</th><th><a href="medchecktip.html#Vol3-No9">Contents</a></th><th><a href="Med&#32;Check-TIP&#32;09-12-27.pdf">PDF(4.8MB)</a></th>
	</tr>
	<tr>
		<th>Aug. 2017,Vol.3, No.8</th><th><a href="medchecktip.html#Vol3-No8">Contents</a></th><th><a href="Med&#32;Check-TIP&#32;08-08-17.pdf">PDF(7.8MB)</a></th>
	</tr>
	<tr>
		<th>Apr. 2017,Vol.3, No.7</th><th><a href="medchecktip.html#Vol3-No7">Contents</a></th><th><a href="Med&#32;Check-TIP&#32;07-04-14.pdf">PDF(3.3MB)</a></th>
	</tr>
	<tr>
		<th>Dec. 2016,Vol.2, No.6</th><th><a href="medchecktip.html#Vol2-No6">Contents</a></th><th><a href="Med&#32;Check-TIP&#32;06-12-12.pdf">PDF(9.9MB)</a></th>
	</tr>
	<tr>
		<th>Aug. 2016,Vol.2, No.5</th><th><a href="medchecktip.html#Vol2-No5">Contents</a></th><th><a href="Med&#32;Check-TIP&#32;05-08-08.pdf">PDF(6.2MB)</a></th>
	</tr>
	<tr>
		<th colspan="2">Supplementary material:</th><th><a href="Frailty&#32;exclusion&#32;bias-theoretical&#32;basis&#32;and&#32;influence&#32;on&#32;Nagoya&#32;City&#32;Study2016-6-6.pdf">PDF(6.3MB)</a></th>
	</tr>
	<tr>
		<th>Apr. 2016,Vol.2, No.4</th><th><a href="medchecktip.html#Vol2-No4">Contents</a></th><th><a href="Med&#32;Check-TIP&#32;04-04-05.pdf">PDF(16MB)</a></th>
	</tr>
	<tr>
		<th colspan="2">Supplement: Cochrane comments</th><th><a href="Suppl&#32;Critical&#32;comments&#32;to&#32;ECDC&#32;by&#32;Cochrane&#32;team.pdf">PDF(1.3MB)</a></th>
	</tr>
	<tr>
		<th>Dec. 2015,Vol.1, No.3</th><th><a href="medchecktip.html#Vol1-No3">Contents</a></th><th><a href="Med&#32;Check-TIP&#32;03-12-01.pdf">PDF(7MB)</a></th>
	</tr>
	<tr>
		<th>Aug. 2015,Vol.1, No.2</th><th><a href="medchecktip.html#Vol1-No2">Contents</a></th><th><a href="Med&#32;Check-TIP&#32;02-08-21.pdf">PDF(5MB)</a></th>
	</tr>
	<tr>
		<th>Apr. 2015,Vol.1, No.1</th><th><a href="medchecktip.html#Vol1-No1">Contents</a></th><th><a href="Med&#32;Check-TIP&#32;01-4-25.pdf">PDF(3MB)</a></th>
	</tr>
	<tr>
		<th colspan="3"><a href="../ejindex.htm">Web MedCheck in English<br />
				<small>former"Kusuri-no-Check in English"： No1(2003) ～No11(2008)</small></a></th>
	</tr>
</table
<br /><br /><br /><br /><br /><br /><br />

<a name="Vol5-No14"></a>
<hr style="height:4px; background-color:#ff9999;">

<p>CONTENTS August 2019,　Vol.5, No.14  <a href="Med&#32;Check&#32;Tip-14-2019-9-10.pdf">PDF(6.9MB)</a></p>
<dl class="tip">Editorial:</dl>
	<dt><b>Does the Japanese Regulator ignore science?　P18</b></dt>

<dl class="tip">Critical Review</dl>
	<dt><b>Critical Assessment of Dementia Guidelines:　p19</b></dt>
		<dd>Don't try to cure but communicate appropriately</dd>
	<dt><b>Critical Assessment of Nocturia Guidelines:  　p25</b></dt>
		<dd>Non-pharmacological treatment is the best</dd>
	<dt><b>Critical Assessment of Guidelines for Low-dose Pills:　p28</b></dt>
		<dd>Thromboembolism may occur in 1 out of 37 high risk women</dd>

<a name="Vol5-No13"></a>
<hr style="height:4px; background-color:#ff9999;">

<p>CONTENTS April 2019,　Vol.5, No.13  <a href="Med&#32;Check&#32;Tip-13-2019-5-3.pdf">PDF(6.1MB)</a></p>
<dl class="tip">Editorial:</dl>
	<dt><b>Accelerated approval, ignoring harm, is a crime　P2</b></dt>
<dl class="tip">New products</dl>
	<dt><b>New Direct-acting Antiviral for Hepatitis C (Epclusa)　p3-6</b></dt>
		<dd>Advance in hepatitis C with prior treatment failure or decompensated cirrhosis</dd>

<dl class="tip">Adverse Reactions</dl>
	<dt><b>Hemorrhage caused by an Anti-influenza Agent, Xofluza　p7-9</b></dt>
		<dd><b>Serious toxicity necessitating suspension of its use</b></dd>

<dl class="tip">Critical Review</dl>
	<dt><b>Critical Assessment of Diabetes Guidelines:　p10-15</b></dt>

<a name="Vol4-No12"></a>
<hr style="height:4px; background-color:#ff9999;">

<p>CONTENTS December 2018,　Vol.4, No.12  <a href="Med&#32;Check-TIP&#32;12-12-18.pdf">PDF(8.5MB)</a></p>
<dl class="tip">Editorial:</dl>
	<dt><b>Dying Cochrane: Could it be resuscitated?　P30</b></dt>
<dl class="tip">New products</dl>
	<dt><b>Herpes zoster subunit vaccine Shingrix: Judgment Reserved　p31</b></dt>
	<dt><b>Baloxavir (Xofluza®) for Influenza: No Value　p37</b></dt>
		<dd>No difference from Tamiflu in efficacy, and suppresses immunity</dd>

<dl class="tip">Adverse Reactions</dl>
	<dt><b>New evidence of severe abnormal behaviors/psychiatric reactions to oseltamivir(Tamiflu)　p40</b></dt>

<dl class="tip">Critical Review</dl>
	<dt><b>Cochrane review on HPV vaccine should be revised:　p41</b></dt>

<dl class="tip">News　p50</dl>
	<dt><b>Cochrane Out of Control: Expulsion of the Prominent Member</b></dt>
	<dt><b>France has delisted anti-dementia agents</b></dt>

<a name="Vol4-No11"></a>
<hr style="height:4px; background-color:#ff9999;">

<p>CONTENTS August 2018,　Vol.4, No.11  <a href="Med&#32;Check-TIP&#32;11-08-29.pdf">PDF(4.2MB)</a></p>
<dl class="tip">Editorial:</dl>
	<dt><b>What we learned from epidemiological studies on drug-induced pneumonia　p16</b></dt>
<dl class="tip">New products</dl>
	<dt><b>A new cholesterol lowering agent: lomitapide is highly toxic　p17</b></dt>
<dl class="tip">Review</dl>
	<dt><b>Japanese Guideline for Hypertension is for disease mongering　P20</b></dt>
		<dd>Medical checkups create “patients” and shorten their lifespan by “treatment”</dd>
<dl class="tip">Adverse Reactions</dl>
	<dt><b>Pneumonia induced by benzodiazepines　P24</b></dt>
		<dd>Evidence shows causal relations</dd>

<a name="Vol4-No10"></a>
<hr style="height:4px; background-color:#ff9999;">

<p>CONTENTS April 2018,　Vol.4, No.10  <a href="Med&#32;Check-TIP&#32;10-05-09.pdf">PDF(2.9MB)</a></p>
<dl class="tip">Editorial:</dl>
	<dt><b>Is the “Right-to-try” a “Right of Patient” ?　p2</b></dt>
<dl class="tip">Review</dl>
	<dt><b>Who benefits from the guidelines?　P3</b></dt>
	<dt><b>Guidelines for influenza treatment in Japan is misleading　p6</b></dt>
	<dt><b>Do general health checks prolong lifespan? 　p11</b></dt>

<a name="Vol3-No9"></a>
<hr style="height:4px; background-color:#ff9999;">

<p>CONTENTS December 2017,　Vol.3, No.9  <a href="Med&#32;Check-TIP&#32;09-12-27.pdf">PDF(4.8MB)</a></p>
<dl class="tip">Editorial:</dl>
	<dt><b>WHO downgraded oseltamivir (Tamiflu)　　　　　　　　　p28</b></dt>
<dl class="tip">New products</dl>
	<dt><b>Hypnotic (sleeping pill), suvorexant (brand name Belsomra)　p29</b></dt>
		<dd class="tipp">A substance that causes narcolepsy and cataplexy</dd>
	<dt><b>Teriparatide　　More harm than benefit　　　　　　　　　P34</b></dt>
<dl class="tip">Review</dl>
	<dt><b>Insomnia, Optimal Sleep Duration and Harm of Sleeping pills　P36</b></dt>
	<dt><b>Pneumonia caused by proton pump inhibitors (PPI)</b></dt>
		<dd> (1) meta-analysis　　　　　　P40</dd>
		<dd>(2) Critical appraisal of a study　P42</dd>

<a name="Vol3-No8"></a>
<hr style="height:4px; background-color:#ff9999;">

<p>CONTENTS August 2017,　Vol.3, No.8  <a href="Med&#32;Check-TIP&#32;08-08-17.pdf">PDF(7.8MB)</a></p>
<dl class="tip">Editorial:</dl>
	<dt><b>Is the intervention really necessary?　　　　　　　　　p13</b></dt>
	<dd>The importance of the epidemiologic evidence</dd>
<dl class="tip">Review</dl>
	<dt><b>Screening does not reduce cervical cancer deaths　　　　p14</b></dt>
		<dd>The best and only protective measure is to have adequate nutrition and sleep</dd>
	<dt><b>Pneumococcal and Hib vaccines for children　　　　　　p20</b></dt>
		<dd>Harms may outweigh benefits: not recommended</dd>

<a name="Vol3-No7"></a>
<hr style="height:4px; background-color:#ff9999;">

<p>CONTENTS April 2017,　Vol.3, No.7  <a href="Med&#32;Check-TIP&#32;07-04-14.pdf">PDF(3.3MB)</a></p>
<dl class="tip">Editorial:</dl>
	<dt><b>Time to wake up from a nightmare</b></dt>
	<dt> "cholesterol=devil" hypothesis</dt>
<dl class="tip">New products</dl>
	<dt><b>Anti PD-1 antibody: pembrolizumab</dt>
		<dd class="tipp">Effective only for non-small cell lung cancer of specific type</dd>
	<dt><b>New Cholesterol Lowering Agents (PCSK9 Inhibitors)</b></dt>
		<dd class="tipp">Infection and neurological diseases increase.</dd>
<dl class="tip">Topics</dl>
		<dd>Top 1 most read for 5 months: paper on cholesterol</dd>
		<dd>RCTs of cholesterol lowering agents of different classes were cancelled in succession</dd>

<a name="Vol2-No6"></a>
<hr style="height:4px; background-color:#ff9999;">

<p>CONTENTS December 2016,　Vol.2, No.6  <a href="Med&#32;Check-TIP&#32;06-12-12.pdf">PDF(9.9MB)</a></p>
<dl class="tip">Editorial:</dl>
	<dt><b>Don’t be misled by new “mab” drugs                   p28</b></dt>
<dl class="tip">New products</dl>
	<dt><b>Nivolumab (brand name: Opdivo)                        p29-34</b></dt>
		<dd>Benefit and harm on survival offset each other: strict restriction on use is needed</dd>
	<dt><b>GLP-1 Agonists (liraglutide)                           p35-42</b></dt>
		<dd>No evidence of improving prognosis in patients with diabetes: Not recommended</dd>

<a name="Vol2-No5"></a>
<hr style="height:4px; background-color:#ff9999;">

<p>CONTENTS Aug. 2016,　Vol.2, No.5  <a href="Med&#32;Check-TIP&#32;05-08-08.pdf">PDF(6.2MB)</a></p>
<dl class="tip">Editorial:</dl>
		<dd>Epidemiologists and biostatisticians, be honest!</dd>
<dl class="tip">Adverse Reactions</dl>
	<dt><b>Symptoms after HPV vaccine:</dt>
		<dd>Typical "frailty exclusion bias" in Nagoya City study</dd>
		<dd>Critical comments from theoretical viewpoints</dd>
<dl class="tip">Supplementary material:</dl>
	<dt><b>Frailty exclusion bias：A theoretical basis and practical influences on Nagoya City Study:<a href="Frailty&#32;exclusion&#32;bias-theoretical&#32;basis&#32;and&#32;influence&#32;on&#32;Nagoya&#32;City&#32;Study2016-6-6.pdf">PDF(6.3MB)</a></b></dt>
<dl class="tip">Adverse Reactions</dl>
	<dt><b>Pioglitazone (brand name: Actos) and bladder cancer: A new type "time-related bias"</b></dt>


<a name="Vol2-No4"></a>
<hr style="height:4px; background-color:#ff9999;">

<p>CONTENTS Apr. 2016,　Vol.2, No.4  <a href="Med&#32;Check-TIP&#32;04-04-05.pdf">PDF(16MB)</a></p>
<dl class="tip">Editorial:</dl>
		<dd>“Talk about harm, not risk” </dd>
<dl class="tip">New Products</dl>
	<dt><b>Memantine</b> (brand name: Memary): No value for dementia</dt>
		<dd>An NMDA antagonist, memantine may induce neurotoxicity</dd>
		<dd>Too many withdrawn cases due to adverse reactions</dd>
	<dt><b>Dutasteride</b> (Zagallo®) for Androgenetic alopecia: </dt>
		<dd>Good in theory, too harmful in practice: cancer, sexual dysfunctions, suicide</dd>
<dl class="tip">Review</dl>
	<dt><b>Cochrane team criticises the ECDC experts' draft advice 
 on oseltamivir use:</b></dt>
<dl class="tip">Supplementary material:</dl>
	<dt><b>Critical comments to ECDC by Cochrane team  <a href="Suppl&#32;Critical&#32;comments&#32;to&#32;ECDC&#32;by&#32;Cochrane&#32;team.pdf">PDF(1.3MB)</a></b></dt>




<a name="Vol1-No3"></a>
<hr style="height:4px; background-color:#ff9999;">

<p>CONTENTS Dec. 2015,Vol.1, No.3  <a href="Med&#32;Check-TIP&#32;03-12-01.pdf">PDF(7MB)</a></p>
<dl class="tip">Editorial:</dl>
		<dd>“Surrogate endpoint” qualify “real advance”? </dd>
<dl class="tip">New Products</dl>
	<dt><b>Anti-HCV agent LDV/SOF combination</b>  (brand name: Harvoni) </dt>
		<dd>8 week treatment may be better to reduce harm and costs with same efficacy</dd>
	<dt><b>Febuxostat</b>(brand name: Febric): <b>Inferior to allopurinol</b></dt>
		<dd>Too frequent cardiovascular events, gouty attacks, serious allergy </dd>
<dl class="tip">Review</dl>
	<dt><b>Is Alteplase Beneficial for Treating Ischemic Stroke?</b></dt>

		<dd>No proven efficacy if it is given 1.5 hours after onset</dd>

<a name="Vol1-No2"></a>
<hr style="height:4px; background-color:#ff9999;">

<p>CONTENTS Aug. 2015,Vol.1, No.2  <a href="Med&#32;Check-TIP&#32;02-08-21.pdf">PDF(5MB)</a></p>
<dl class="tip">Editorial:</dl>
		<dd>We want good medicines! </dd>
<dl class="tip">New Products</dl>
	<dt><b>Dabigatran:</b>  potentially harmful: See also <a href="dabigatran&#32;Supplementary&#32;materials-2.pdf"><b>Supplementary materials: PDF</b> (4.6MB)</a></dt>
		<dd>The safe use is compromised without monitoring and an antagonist<br />
				Optimal dose may be lower: Subgroup analysis indicates<br />
				Information for the patient (Dabigatran)</dd>
	<dt><b>Lubiprostone: </b></dt>
		<dd>Too harmful and expensive for general use as a laxative<br />
				Plain language summary</dd>
<dl class="tip">Adverse Reactions</dl>
		<dd>Propofol-induced death in children: at a Univ. Hospital</dd>
		<dd>Plain language summary</dd>
<dl class="tip">Plain Language summary</dl>
		<dd>Dabigatran (information for the patient) <br />
		Lubiprostone <br />
		Propofol</dd>

<a name="Vol1-No1"></a>
<hr style="height:4px; background-color:#ff9999;">

<p>CONTENTS Apr. 2015,Vol.1, No.1  <a href="Med&#32;Check-TIP&#32;01-4-25.pdf">PDF(3MB)</a></p>
<dl class="tip">Editorial:</dl>
		<dd>An independent drug bulletin for medical practice </dd>
<dl class="tip">New Products</dl>
	<dt># SGLT-2 inhibitors:  Unacceptable products--can we call these “medicines”?</dt>
		<dd>Were the harms warned after marketing known before approval?</dd>
	<dt># Methadone (Limited use): Useful only in opioid rotation with special precautions</dt>
		<dd>Why is it useful in opioid rotation?  What precautions are needed?</dd>
<dl class="tip">Reviews</dl>
	<dt># H.pylori eradication may shorten life span: </dt>
		<dd>Gastric cancer decreases by H.pylori eradication. Why life span may shorten?</dd>
		<dd>What diseases and why other diseases increase? What are the underlying mechanisms?</dd>
	<dt># Harm of HPV vaccine: Latest information and examination of epidemiological studies</dt>
		<dd> “I have never seen such serious diseases in teen age girls”, many specialists say.</dd>
		<dd>Do RCTs prove the safety of HPV vaccines? </dd>
		<dd>Do epidemiologic studies prove the safety of HPV vaccines?</dd>
		<dd>Is the prevalence same as the incidence? What is the “healthy vaccinee effect” </dd>
<dl class="tip">Plain Language summary</dl>
	<dt># SGLT-2 inhibitors: inaccurate to call these “medicines”</dt>
		<dd>What is diabetes?  What is insulin? <br />
	Target of treatment is NOT to normalize the blood glucose level. Then what is the target? </dd>
	<dt># "Pylori" bacteria removal may shorten life </dt>
	<dt># Harm of HPV vaccine: epidemiologic studies do not prove safety</dt>

	</div><!-- contents -->
<!-- ここからコピー -->
	<div id="footer">
		<p>&copy;2000-2019　by　NPOJIP　All　Rights　Reserved.</p>
	</div><!-- footer -->
</div><!-- wrapper -->
<!-- ここまでコピー -->
</body>
</html>
<!-- ここまでコピー -->
